prognostic scoring system

prognostic scoring system

Any scoring to help predict outcome(s) and identify Pts and clinical situations in which the potential value of intensive care is low, while the burden of therapy is high, providing a numerical prediction of mortality. See APACHE II, MPS, PRISM, SAPS, TISS.
References in periodicals archive ?
The blast count is part of that International Prognostic Scoring System (IPSS) for MDS.
The two-stage study will be conducted at approximately 25 sites and is expected to enroll up to 120 patients with high and very high risk MDS per the Revised International Prognostic Scoring System (IPSS-R).
The phase 1/2, open-label, multi-centre clinical trial is intended to assess the safety and activity of 33A administered in combination with azacitidine in patients with earlier untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk MDS.
Se evaluaron diversas caracteristicas clinicas incluyendo la clasificacion de riesgo segun el International Prognostic Scoring System (IPSS), el Revised International Prognostic Scoring System (IPSS-R), el WHO classification-based Prognostic Scoring System (WPSS), y la escala de riesgo del MD Anderson Cancer Center (MDAS).
Since 1974, when John Ranson reported the first prognostic scoring system for acute pancreatitis, a large variety of multifactorial systems and single biochemical markers have been extensively evaluated with the aim of predicting the severity of the disease.
After an introductory discussion by author VJL, the panel specifically reviewed the treatment options for patients in the lower-, intermediate- and higher-risk groups, according to the International Prognostic Scoring System (IPSS) categories LOW, intermediate-1 (INT-1) and HIGH (IPSS category HIGH, INT-2).
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
S Food and Drug Administration (FDA) on May 2, 2006 for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
To predict the time to first treatment (TTFT) in patients of early stages, we evaluated the prognostic role of conventional markers as well as cytogenetic abnormalities and combined them together in a new prognostic scoring system, the CLL prognostic index (CLL-PI).
Under the phase 2/3 clinical trial, imetelstat will be examined in transfusion dependent patients with International Prognostic Scoring System Low or Intermediate-1 risk MDS that have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent.